Welcome to our dedicated page for Briacell Therapeutics news (Ticker: BCTX), a resource for investors and traders seeking the latest updates and insights on Briacell Therapeutics stock.
BriaCell Therapeutics Corp. (BCTX) generates frequent news flow as a clinical-stage biotechnology company developing novel immunotherapies for cancer, with a strong focus on metastatic breast cancer. News about BriaCell often centers on clinical trial milestones, emerging efficacy and safety data, biomarker analyses, and platform advancements across its Bria-IMT™, Bria-OTS™, and Bria-OTS+™ programs.
Investors and researchers following BCTX news can track updates on the pivotal Phase 3 Bria-IMT trial in advanced metastatic breast cancer, including enrollment progress, interim analyses, and presentations at major scientific meetings such as the San Antonio Breast Cancer Symposium (SABCS®). Company releases describe survival outcomes, progression-free survival signals, and potential predictive biomarkers like neutrophil-to-lymphocyte ratio, delayed-type hypersensitivity responses, and Th1-biased cytokine signatures.
BriaCell’s news stream also highlights developments in its Bria-OTS and Bria-OTS+ off-the-shelf immunotherapy platforms. Announcements include clinical observations such as sustained complete resolution of lung metastasis in a metastatic breast cancer patient treated with Bria-OTS, as well as preclinical data showing robust innate and adaptive immune activation by Bria-OTS+ candidates Bria-BRES+™ and Bria-PROS+™ in breast and prostate cancer models.
Additional coverage includes corporate and pipeline updates from BriaPro Therapeutics Corp., BriaCell’s subsidiary, and its AI-driven collaboration with Receptor.AI to design isoform-selective kinase inhibitors. For those monitoring BCTX, this news page provides a centralized view of regulatory designations, trial recognitions in scientific publications, collaborative research announcements, and detailed scientific poster summaries. Regular visits can help readers follow how BriaCell’s immunotherapy platforms evolve from preclinical research through late-stage clinical evaluation.
BriaCell Therapeutics Corp. (BCTX, BCTXW) will present new data on its immunotherapy, Bria-IMT™, at the SITC 37th Annual Meeting from November 10-12, 2022, in Boston, MA. The presentation highlights clinical benefits observed in advanced breast cancer patients, showcasing extended survival and tumor reductions in those matching specific HLA types. The session aims to further optimize off-the-shelf personalized immunotherapies. The poster presentation will be available online afterwards, offering insights into BriaCell's innovative approaches to cancer treatment.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has secured an exclusive license from the University of Maryland, Baltimore County to develop Soluble CD80 (sCD80) for cancer treatment. This innovative biologic agent aims to reverse immune suppression in cancer patients and may enhance anti-tumor immunity. Supported by promising animal study data, BriaCell plans to explore sCD80 as a standalone treatment or in combination with existing immunotherapies. The licensing agreement includes royalty payments to UMBC upon commercialization.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has partnered with Waisman Biomanufacturing to manufacture Bria-Pros™, a personalized immunotherapy for advanced prostate cancer. This collaboration aims to ensure the production of clinical supplies under good manufacturing practices (GMP). Bria-Pros™ consists of multiple HLA-specific immunotherapy cell lines tailored to patients' HLA types. The Phase I/II clinical trial is anticipated to begin after completion of manufacturing and regulatory processes. With prostate cancer being a significant health concern, this innovative approach may provide new treatment options.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has entered a research collaboration with Harvard Medical School, led by Dr. Joan S. Brugge, to identify novel anti-cancer treatment targets. The focus will be on enhancing tumor cell response to chemotherapy and immunotherapies for lung, head and neck, cervical, and bladder cancers. Under the one-year agreement, BriaCell may negotiate licenses for any innovations developed. This partnership aims to address significant challenges in precision cancer treatments and aligns with BriaCell's strategy for developing effective cancer therapies.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced significant findings from a publication on its lead candidate, Bria-IMT™, for advanced breast cancer. The research, published in Recent Patents on Anti-Cancer Drug Discovery, demonstrated Bria-IMT™'s ability to rapidly destroy tumors in patients with matching HLA types, aligning with BriaCell's strategy for off-the-shelf personalized immunotherapy. Clinical data indicated tumor shrinkage and an overall survival exceeding 33 months in some patients, affirming the drug's efficacy and safety.
Creatv Bio announced the results of its LifeTracDx® blood test for predicting response in metastatic breast cancer (mBC) therapy, to be presented at the ASCO Annual Meeting from June 3-7, 2022, in Chicago, IL. The study highlights the test's ability to assess tumor responsiveness after one therapy cycle, regardless of the therapy type. Notably, the presentation will include collaborations with BriaCell Therapeutics (NASDAQ: BCTX) as part of ongoing clinical developments. This innovative approach may enhance treatment personalization for mBC patients and is part of ongoing research efforts.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has activated Hoag Memorial Hospital and re-engaged Sylvester Comprehensive Cancer Center to enhance patient enrollment in its Phase I/IIa clinical trial for Bria-IMT™ in combination with Incyte’s therapies. The addition of these sites aims to accelerate patient recruitment, as BriaCell prepares for discussions with the FDA regarding safety and efficacy data. This phase of the trial includes several active sites across the U.S., representing BriaCell's ongoing commitment to advancing immunotherapy for advanced breast cancer.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) announced that the FDA has granted Fast Track status to its lead immunotherapy candidate, Bria-IMT™, aimed at treating metastatic breast cancer. This designation allows for quicker communication with the FDA, potentially leading to earlier drug approval and patient access. BriaCell is currently enrolling patients in a Phase I/IIa clinical trial, combining Bria-IMT™ with Incyte's checkpoint inhibitor retifanlimab and immunomodulator epacadostat.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has developed Bria-OTS™, a novel off-the-shelf personalized immunotherapy for advanced breast cancer, discussed during the AACR Annual Meeting 2022. This innovative treatment aims to match patients' HLA types using a simple saliva test, enhancing the likelihood of clinical benefits. The Bria-OTS™ therapy utilizes genetically modified cell lines to cater to over 99% of the population, accelerating treatment without complex manufacturing processes. An open-label Phase I/IIa clinical trial is anticipated to evaluate its safety and efficacy.
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) has developed Bria-OTS™, an off-the-shelf personalized immunotherapy for advanced breast cancer. Currently in production at a cGMP facility, Bria-OTS™ is undergoing quality control testing in preparation for an upcoming Phase I/IIa clinical trial. Collaborating with the National Cancer Institute, BriaCell aims to optimize treatment based on patients' HLA types. The company will present details about Bria-OTS™ at the American Association for Cancer Research Annual Meeting on April 12, 2022.